Kinetics of inhibition of purified bovine neutrophil matrix metalloproteinase 9 by low–molecular-weight inhibitors

Gregory A. Bannikov Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210.

Search for other papers by Gregory A. Bannikov in
Current site
Google Scholar
PubMed
Close
 PhD
,
Jeffrey Lakritz Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210.

Search for other papers by Jeffrey Lakritz in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Christopher Premanandan Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210.

Search for other papers by Christopher Premanandan in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
John S. Mattoon Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210.

Search for other papers by John S. Mattoon in
Current site
Google Scholar
PubMed
Close
 DVM
, and
Eric J. Abrahamsen Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210.

Search for other papers by Eric J. Abrahamsen in
Current site
Google Scholar
PubMed
Close
 DVM

Abstract

Objective—To measure the effects of lowmolecular-weight inhibitors on the activity of bovine neutrophil matrix metalloproteinase 9 (MMP-9).

Sample Population—Bovine MMP-9 purified from bovine neutrophilconditioned medium.

Procedures—Neutrophils were degranulated by stimulation with phorbol ester. Enzyme purification was performed by use of gelatin affinity and gel-filtration chromatography. Activated enzyme was incubated with inhibitors prior to addition of substrate (gelatin fluorescein conjugate or fluorogenic peptide). Rates of enzymatic cleavage were determined by monitoring fluorescence as the reactions progressed. Values of IC50 (molar concentration of compound that inhibits specific activity by 50%) and KI (in vitro inhibition constant) were determined.

Results—Rates of enzymatic activity of monomeric and dimeric bovine MMP-9 measured by use of gelatin and peptide substrates were linear with respect to time and concentrations of enzyme and substrate. The MMP-9 was potently inhibited by hydroxamic acids (IC50 for gelatin, 29.2 to 55.7nM; IC50 for peptide, 4.8 to 24.6nM; KI, 0.2 to 0.5nM), whereas tetracyclines (IC50 for gelatin, 30.1 to 112.7MM; IC50 for peptide, 48.0 to 123.8MM; KI, 25.2 to 61.4µM) and chlorhexidine (IC50 for gelatin, 139.1MM; IC50 for peptide, 672.5MM to 1.7mM; KI, 495.0 to 663.0MM) had limited inhibition. Gelatinase-specific inhibitor SB-3CT had intermediate potency (IC50 for peptide, 185.0 to 290.0nM; KI, 66.5 to 86.0nM).

Conclusions and Clinical Relevance—Bovine MMP-9 was potently inhibited by hydroxamic acids and gelatinase inhibitor. These compounds may be useful as modulators of neutrophil-mediated protease activity in cattle.

Abstract

Objective—To measure the effects of lowmolecular-weight inhibitors on the activity of bovine neutrophil matrix metalloproteinase 9 (MMP-9).

Sample Population—Bovine MMP-9 purified from bovine neutrophilconditioned medium.

Procedures—Neutrophils were degranulated by stimulation with phorbol ester. Enzyme purification was performed by use of gelatin affinity and gel-filtration chromatography. Activated enzyme was incubated with inhibitors prior to addition of substrate (gelatin fluorescein conjugate or fluorogenic peptide). Rates of enzymatic cleavage were determined by monitoring fluorescence as the reactions progressed. Values of IC50 (molar concentration of compound that inhibits specific activity by 50%) and KI (in vitro inhibition constant) were determined.

Results—Rates of enzymatic activity of monomeric and dimeric bovine MMP-9 measured by use of gelatin and peptide substrates were linear with respect to time and concentrations of enzyme and substrate. The MMP-9 was potently inhibited by hydroxamic acids (IC50 for gelatin, 29.2 to 55.7nM; IC50 for peptide, 4.8 to 24.6nM; KI, 0.2 to 0.5nM), whereas tetracyclines (IC50 for gelatin, 30.1 to 112.7MM; IC50 for peptide, 48.0 to 123.8MM; KI, 25.2 to 61.4µM) and chlorhexidine (IC50 for gelatin, 139.1MM; IC50 for peptide, 672.5MM to 1.7mM; KI, 495.0 to 663.0MM) had limited inhibition. Gelatinase-specific inhibitor SB-3CT had intermediate potency (IC50 for peptide, 185.0 to 290.0nM; KI, 66.5 to 86.0nM).

Conclusions and Clinical Relevance—Bovine MMP-9 was potently inhibited by hydroxamic acids and gelatinase inhibitor. These compounds may be useful as modulators of neutrophil-mediated protease activity in cattle.

All Time Past Year Past 30 Days
Abstract Views 42 0 0
Full Text Views 348 239 27
PDF Downloads 184 153 9
Advertisement